Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

EQI decreases malonyl-CoA levels in <i>S</i>. <i>aureus</i>. by Erica C. Larson (1344687)

Dex increases migration independently of WNT5A/Frizzled-5 interaction. by Martin Crozier (13804275)

Sirt5 KO induces increased lysine succinylation and decreased ATP synthase activity in mouse heart mitochondria. by Mengli Zhang (6331172)

Activin A decreases MPTP and LPS-induced inflammation. by Sandy Stayte (728461)

“…<p>Stereological quantification of the left SNpc demonstrated activin A significantly decreased the number of GFAP-immunoreactive cells (A) and Iba1-immunoreactive cells (B) in the SNpc following MPTP. …”

Pelvis and femur shape prediction using principal component analysis for body model on seat comfort assessment. Impact on the prediction of the used palpable anatomical landmarks a... by Léo Savonnet (7314200)

“…Results also show that the PCA based method is a good alternative to predict hip and lumbosacral joint centers with an average error of 5.0 and 9.2 mm respectively.…”

Inhibition of Akt but not Erk signaling is synergistic with atorvastatin. by Colin H. Beckwitt (2037196)

Grey matter concentration decreases for (A) tinnitus duration. by Sven Vanneste (202029)

“…<p>Grey matter decrease projected onto a T1-weighted image. Maximum intensity projection with a threshold of <i>p</i> < .001 (uncorrected) at both voxel and cluster level. …”

RDV and EIDD2801 EC₅₀ and fold-change in VeroE6-ACE2-TMPRSS2. by Agnieszka M. Szemiel (10196243)

DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

Decreased expression of genes related with cell cycle and growth signaling in the lung tissue during infection with HeV and NiV-B. by Alberto J. Leon (132911)

BoNT/A (3.5 U/kg) decreases dural extravasation in IoNC-injured rats which is prevented by intraganglionic colchicine. by Boris Filipović (336089)

Dose-dependent inhibition of V-ATPase with Bafilomycin A1 decreases LysoTracker Red fluorescence and increases Lyso-pHluorin fluorescence. by Yarden Golan (5924594)

BoNT/A (3.5 U/kg) decreases IoNC-induced mechanical allodynia which is prevented by intraganglionic colchicine pretreatment. by Boris Filipović (336089)

Table 5_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx by Fengwang Xue (22245625)

“…The ACM rates were 22.5% at 30 days and rose to 26.0% at 90 days. Multivariable Cox regression showed that, after full adjustment for potential confounders, every 2-unit decrease in PNI was associated with a 10% higher 30-day mortality hazard (HR = 1.10, 95% CI = 1.05–1.15, p < 0.001) and a 9% higher 90-day mortality hazard (HR = 1.09, 95% CI = 1.04–1.14, p < 0.001). …”